NeoSep1 Clinical Trial Expands to India to Combat Drug-Resistant Neonatal Sepsis and Rising Antimicrobial Resistance

Recent Developments:

• The NeoSep1 Clinical Trial, funded by the Global Antibiotic Research and Development Partnership (GARDP) Foundation, has expanded to India to evaluate improved antibiotic treatment strategies for drug-resistant neonatal sepsis.
• The trial aims to generate evidence for treating newborn sepsis caused by multidrug-resistant bacteria, particularly in low- and middle-income countries, where resistance patterns differ significantly from high-income nations.

NeoSep1 Clinical Trial:

About the Trial:

• NeoSep1 is the world's first large international clinical trial specifically designed to identify effective antibiotic regimens for hospitalised newborns with sepsis.
• The trial focuses on treating infections caused by multidrug-resistant pathogens, which are increasingly reducing the effectiveness of standard antibiotic therapies.
• The study is coordinated under the Global Antibiotic Research and Development Partnership (GARDP) in collaboration with international research institutions and participating hospitals.

Significance for India:

• India carries one of the world's highest burdens of neonatal sepsis, making the trial highly relevant for improving neonatal survival.
• The bacterial profile responsible for newborn sepsis in India differs from that observed in many developed countries, requiring locally appropriate treatment strategies.
• The trial is expected to generate evidence-based treatment protocols that can strengthen neonatal healthcare and reduce mortality associated with antimicrobial resistance.

Neonatal Sepsis:

Meaning:

• Neonatal Sepsis is a life-threatening bloodstream infection occurring in infants below 90 days of age.
• Premature babies and infants with low birth weight are at significantly higher risk because of their immature immune systems.

Types:

• Early-Onset Neonatal Sepsis (EONS): Develops within the first 72 hours after birth and is commonly associated with maternal infections transmitted during delivery.
• Late-Onset Neonatal Sepsis (LONS): Occurs between 72 hours and 28–90 days after birth and is generally linked to hospital-acquired or community-acquired infections.

Major Causative Organisms in India:

• Unlike many developed countries where Group B Streptococcus is a leading cause, neonatal sepsis in India is predominantly caused by drug-resistant Gram-negative bacteria.
• Important pathogens include:
• Klebsiella pneumoniae.
• Escherichia coli.
• Acinetobacter species.
• Pseudomonas aeruginosa.

Clinical Features:

• Common symptoms include fever, rapid breathing, fast heart rate, poor feeding, lethargy, confusion, and body pain.
• Untreated infection may progress to septic shock, multiple organ dysfunction, and death.

Disease Burden in India:

• Neonatal sepsis contributes to nearly 30–40% of neonatal deaths in India.
• An estimated 2–2.5 lakh neonatal deaths each year are considered preventable through timely diagnosis and effective treatment.

Prevention:

• Maintaining hand hygiene, infection prevention measures, clean water, safe sanitation, safe childbirth practices, vaccination, exclusive breastfeeding, and adequate maternal nutrition significantly reduce the risk of neonatal infections.

Antimicrobial Resistance (AMR):

Meaning:

• Antimicrobial Resistance (AMR) refers to the ability of microorganisms to survive exposure to antimicrobial medicines that previously killed or inhibited them.
• The phenomenon affects bacteria, viruses, fungi, and parasites, reducing the effectiveness of antibiotics, antivirals, antifungals, and antiparasitic medicines.

Mechanism:

• Microorganisms develop resistance through genetic mutations and natural selection, particularly when antimicrobial medicines are misused or overused.
• Resistant microbes multiply and spread, making infections increasingly difficult to treat.

Consequences:

• Increased treatment failure.
• Higher disease transmission.
• Longer hospitalisation.
• Greater healthcare expenditure.
• Increased disability and mortality.
• Rising risk of untreatable multidrug-resistant infections.

Global Concern:

• The World Health Organization (WHO) recognises Antimicrobial Resistance as one of the top global public health threats of the 21st century.
• Without effective interventions, antimicrobial resistance could become a major obstacle to modern medicine, affecting surgery, cancer treatment, organ transplantation, and neonatal care.

Factors Responsible for Rising Antimicrobial Resistance in India:

Excessive and Irrational Antibiotic Use:

• Over-prescription, self-medication, and irrational use of antibiotics accelerate the emergence of resistant microorganisms.

Poor Infection Prevention and Hygiene:

• Inadequate sanitation and weak infection-control practices in healthcare facilities facilitate the spread of resistant pathogens.

Inadequate Diagnostic Capacity:

• Antibiotics are frequently prescribed without laboratory confirmation, increasing unnecessary antimicrobial exposure.

Pharmaceutical Waste:

• Improper disposal of antibiotic manufacturing waste contaminates the environment and promotes the evolution of resistant bacteria.

Unregulated Use in Livestock:

• Antibiotics are widely used in animal husbandry, dairy farming, and poultry production, contributing to resistance across human and animal populations.

High Population Density and Mass Gatherings:

• Large religious gatherings, political events, and crowded social functions create conditions favourable for rapid transmission of infectious diseases.

Weak Public Awareness:

• Limited awareness regarding appropriate antibiotic use and incomplete treatment courses further accelerates antimicrobial resistance.

Government Initiatives to Combat Antimicrobial Resistance:

National Programme on AMR Containment:

• Launched during the 12th Five-Year Plan (2012–2017) to strengthen national surveillance and containment efforts.
• The programme focuses on:
• Establishing laboratory-based AMR surveillance.
• Monitoring antimicrobial consumption.
• Promoting antimicrobial stewardship.
• Strengthening infection prevention and control measures.

Red Line Campaign:

• Prescription-only antibiotics are marked with a red line to discourage indiscriminate use and self-medication.

National Action Plan on AMR (2017):

• India became one of the earliest countries to adopt a comprehensive National Action Plan on Antimicrobial Resistance.
• The plan follows the One Health Approach involving coordinated action across human health, veterinary health, agriculture, food safety, and environmental sectors.

AMR Surveillance and Research Network (AMRSN):

• Established by the Indian Council of Medical Research (ICMR) in 2013.
• The network monitors resistance trends, generates scientific evidence, and supports national policy formulation.

Research and International Collaboration:

• ICMR collaborates with national and international institutions for developing new antibiotics, improving diagnostics, and strengthening antimicrobial research.

National Centre for Disease Control (NCDC):

• The National Centre for Disease Control coordinates national surveillance, laboratory capacity building, and infection prevention programmes related to antimicrobial resistance.

Challenges in Combating AMR:

Limited Laboratory Infrastructure:

• Uneven diagnostic capacity delays accurate identification of resistant pathogens.

Implementation Gaps:

• Resource constraints affect effective implementation of the National Action Plan on AMR, particularly at State and district levels.

Shortage of New Antibiotics:

• Development of novel antimicrobial drugs remains limited because of high research costs and relatively low commercial returns.

Environmental Transmission:

• Antibiotic residues released into soil and water contribute to the environmental spread of antimicrobial resistance.

Way Forward:

Regulating Antibiotic Use:

• Antibiotic use should be strictly regulated across human healthcare, veterinary medicine, agriculture, and food production.

Strengthening Diagnostic Capacity:

• Rapid and affordable diagnostic facilities should be expanded to ensure evidence-based antibiotic prescribing.

Improving Infection Prevention:

• Better sanitation, vaccination, hand hygiene, hospital infection-control practices, and clean water supply should be prioritised.

Promoting Rational Antibiotic Use:

• Doctors should prescribe antibiotics only when clinically indicated, while citizens should avoid self-medication and complete prescribed treatment courses.

Strengthening National Action Plan:

• Adequate financial resources, inter-ministerial coordination, and continuous monitoring should improve implementation of the National Action Plan on AMR.

Adopting the One Health Approach:

• Integrated action involving human health, animal health, agriculture, and the environment is essential because antimicrobial resistance transcends sectoral boundaries.

Value Addition for UPSC:

One Health Approach:

• The One Health Approach recognises that the health of humans, animals, plants, and ecosystems is interconnected and requires coordinated policy interventions.

WHO AWaRe Classification of Antibiotics:

• The World Health Organization (WHO) classifies antibiotics into Access, Watch, and Reserve categories to promote rational prescribing and reduce antimicrobial resistance.

WHO Priority Pathogens List:

• The World Health Organization periodically identifies priority antibiotic-resistant bacteria requiring urgent research and development of new antimicrobial medicines.

Sustainable Development Goal Linkages:

• SDG 3: Good Health and Well-being.
• SDG 6: Clean Water and Sanitation.
• SDG 2: Zero Hunger through safer livestock and food production systems